Total Payments
$103,211
2024 Payments
$81,339
Companies
6
Transactions
45
Payment Breakdown by Category
Research$98,282 (95.2%)
Travel$3,577 (3.5%)
Food & Beverage$1,100 (1.1%)
Consulting$200.00 (0.2%)
Education$32.27 (0.0%)
Gifts$20.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $98,282 | 21 | 95.2% |
| Travel and Lodging | $3,577 | 12 | 3.5% |
| Food and Beverage | $1,100 | 9 | 1.1% |
| Consulting Fee | $200.00 | 1 | 0.2% |
| Education | $32.27 | 1 | 0.0% |
| Gift | $20.00 | 1 | 0.0% |
Payments by Type
Research
$98,282
21 transactions
General
$4,928
24 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $89,354 | 14 | $0 (2024) |
| Allergan, Inc. | $8,000 | 1 | $0 (2020) |
| AstraZeneca UK Limited | $2,321 | 11 | $0 (2019) |
| PFIZER INC. | $2,117 | 9 | $0 (2021) |
| Corcept Therapeutics | $1,387 | 9 | $0 (2023) |
| Novo Nordisk Inc | $32.27 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $81,339 | 2 | Eli Lilly and Company ($81,339) |
| 2023 | $2,584 | 12 | Corcept Therapeutics ($1,387) |
| 2022 | $3,561 | 5 | Eli Lilly and Company ($3,529) |
| 2021 | $2,865 | 5 | Eli Lilly and Company ($2,845) |
| 2020 | $8,445 | 2 | Allergan, Inc. ($8,000) |
| 2019 | $4,417 | 19 | AstraZeneca UK Limited ($2,321) |
All Payment Transactions
45 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $81,133.00 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY | ||||||
| 09/23/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $206.00 | Research |
| Study: A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | ||||||
| 09/05/2023 | Eli Lilly and Company | — | — | In-kind items and services | $535.01 | Research |
| Study: A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | ||||||
| 08/23/2023 | Corcept Therapeutics | Korlym (Drug) | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $354.99 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $293.55 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $97.66 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $81.18 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $70.32 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/11/2023 | Corcept Therapeutics | Korlym (Drug) | — | In-kind items and services | $30.48 | Research |
| Study: CATALYST • Category: Endocrinology | ||||||
| 05/10/2023 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $194.69 | General |
| Category: Endocrinology | ||||||
| 05/10/2023 | Corcept Therapeutics | Korlym (Drug) | Travel and Lodging | Cash or cash equivalent | $64.26 | General |
| Category: Endocrinology | ||||||
| 01/31/2023 | Eli Lilly and Company | — | — | In-kind items and services | $291.00 | Research |
| Study: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 01/11/2023 | Eli Lilly and Company | — | — | In-kind items and services | $370.53 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | ||||||
| 07/27/2022 | Novo Nordisk Inc | Ozempic (Drug) | Education | In-kind items and services | $32.27 | General |
| Category: Diabetes | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $447.00 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | ||||||
| 04/29/2022 | Eli Lilly and Company | — | — | In-kind items and services | $436.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 03/08/2022 | Eli Lilly and Company | — | — | In-kind items and services | $1,678.00 | Research |
| Study: A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | ||||||
| 01/05/2022 | Eli Lilly and Company | — | — | In-kind items and services | $968.00 | Research |
| Study: A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | ||||||
| 12/08/2021 | Eli Lilly and Company | — | — | In-kind items and services | $2,164.18 | Research |
| Study: A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | ||||||
| 06/04/2021 | PFIZER INC. | — | Gift | In-kind items and services | $20.00 | General |
| 05/10/2021 | Eli Lilly and Company | — | — | In-kind items and services | $189.00 | Research |
| Study: A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | ||||||
| 03/02/2021 | Eli Lilly and Company | — | — | In-kind items and services | $249.01 | Research |
| Study: EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | ||||||
| 01/29/2021 | Eli Lilly and Company | — | — | In-kind items and services | $242.50 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
| 11/05/2020 | Allergan, Inc. | — | — | Cash or cash equivalent | $8,000.00 | Research |
| Study: Androderm 24-Hr ABPM | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY OF ONCE-WEEKLY TIRZEPATIDE PLUS MIBAVADEMAB COMPARED WITH TIRZEPATIDE ALONE IN ADULT PARTICIPANTS WITH OBESITY | Eli Lilly and Company | $81,133 | 1 |
| Androderm 24-Hr ABPM | Allergan, Inc. | $8,000 | 1 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $3,842 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $1,123 | 3 |
| A PHASE 4, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF GALCANEZUMAB VERSUS RIMEGEPANT IN ADULT PARTICIPANTS WITH EPISODIC MIGRAINE | Eli Lilly and Company | $968.00 | 1 |
| CATALYST | Corcept Therapeutics | $928.18 | 6 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $696.01 | 2 |
| A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly and Company | $535.01 | 1 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | Eli Lilly and Company | $370.53 | 1 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) | Eli Lilly and Company | $291.00 | 1 |
| A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | Eli Lilly and Company | $206.00 | 1 |
| A RANDOMIZED, PHASE 3, OPEN LABEL TRIAL COMPARING THE EFFECT OF THE ADDITION OF TIRZEPATIDE ONCE WEEKLY VERSUS INSULIN LISPRO (U100) THREE TIMES DAILY IN PARTICIPANTS WITH TYPE 2 DIABETES INADEQUATELY CONTROLLED ON INSULIN GLARGINE (U100) WITH OR WITHOUT METFORMIN (SURPASS 6) | Eli Lilly and Company | $189.00 | 1 |
About Dr. Mark Leibowitz, M.D
Dr. Mark Leibowitz, M.D is a Internal Medicine healthcare provider based in Long Beach, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/09/2007. The National Provider Identifier (NPI) number assigned to this provider is 1144352907.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Leibowitz, M.D has received a total of $103,211 in payments from pharmaceutical and medical device companies, with $81,339 received in 2024. These payments were reported across 45 transactions from 6 companies. The most common payment nature is "" ($98,282).
Ad
Practice Information
- Specialty Internal Medicine
- Location Long Beach, CA
- Active Since 03/09/2007
- Last Updated 05/28/2013
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1144352907
Products in Payments
- Korlym (Drug) $1,387
- Ozempic (Drug) $32.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Long Beach
Jennifer Connelly, D.o, D.O
Internal Medicine — Payments: $275,877
Internal Medicine $275,877
Dr. Mark Lee, Md, MD
Internal Medicine — Payments: $142,649
Internal Medicine $142,649
Dr. Steven Appleby, Md, MD
Internal Medicine — Payments: $101,644
Internal Medicine $101,644
Dr. Milan Sheth, Md, MD
Internal Medicine — Payments: $71,682
Internal Medicine $71,682
Katya Corado, M.d, M.D
Internal Medicine — Payments: $30,357
Internal Medicine $30,357
Dr. Diane Chau, Md, MD
Internal Medicine — Payments: $26,560
Internal Medicine $26,560